不同部位食管癌放疗患者近远期疗效、血清TSP1、VEGF水平及生存率分析

Short-term and long-term efficacy,serum TSP1,VEGF levels and survival rate in patients with esophageal cancer radiotherapy at different sites

目的分析不同部位食管癌放疗患者近远期疗效、血清血小板应答蛋白1(TSP1)和血管内皮生长因子(VEGF)水平及生存率。方法回顾性选取2013年2月至2015年2月在徐州医科大学附属医院收治的食管癌患者100例,按照肿瘤发生的部位不同分为2组:颈胸上段组50例,胸中下段组50例。比较2组患者一般资料与肿瘤特征,放疗后的近远期疗效,放疗前后血清TSP1、VEGF水平,3、5年的生存率。结果2组患者一般资料与肿瘤特征比较差异均无统计学意义(P>0.05)。近期疗效:放疗后颈胸上段组患者的总有效率[82.00%(41/50)]高于胸中下段组[66.00%(33/50)],差异无统计学意义(P>0.05);远期疗效:放疗后颈胸上段组患者3、5年局部控制率分别为56.00%(28/50)、40.00%(20/50),高于胸中下段组的36.00%(18/50)、20.00%(10/50),差异具有统计学意义(P<0.05)。2组患者放疗前后血清TSP1、VEGF水平比较,差异无统计学意义(P>0.05)。颈胸上段组3、5年生存率分别为76.00%(38/50)、60.00%(30/50),高于胸中下段组的56.00%(28/50)、36.00%(18/50),差异具有统计学意义(P<0.05)。结论放疗对颈胸上段食管癌的疗效较胸中下段食管癌更为理想,可提高颈胸上段食管癌的远期疗效和生存率,对TSP1、VEGF水平影响无显著差异。

Objective To analyze the short-term and long-term efficacy,serum thrombospondin 1(TSP1),vascular endothelial growth factor receptor(VEGF)levels and survival rate in patients with esophageal cancer at different sites.Methods A total of 100 patients with esophageal cancer radiotherapy admitted to Affiliated Hospital of Xuzhou Medical University from February 2013 to February 2015 were selected and divided into the upper cervical thoracic group and the lower middle thoracic group according to the location of the tumor with 50 cases in each group.The general data and tumor characteristics,short-term and long-term efficacy after radiotherapy,TSP1 and VEGF levels were compared between the two groups,and the 3-year and 5-year survival rates were recorded.Results There was no significant difference in general data and tumor characteristics between the two groups of patients(P>0.05).For the short-term efficacy,the total effective rate of patients in the upper cervical thorax group after radiotherapy was higher than in the lower middle thoracic group[82.00%(41/50)vs.66.00%(33/50)],and there was no statistically significant difference between the two groups(P>0.05).For long-term efficacy,the local control rates of patients in the upper cervical thoracic group after radiotherapy at 3-year and 5-year were 56.00%(28/50)and 40.00%(20/50),respectively,which was higher than 36.00%(18/50)and 20.00%(10/50)in the lower middle thoracic group(P<0.05).There was no significant difference in serum TSP1 and VEGF levels between the two groups before and after radiotherapy(P>0.05).The 3-year and 5-year survival rates of the upper cervical thoracic group were 56.00%(28/50)and 20.00%(10/50),which were higher than 36.00%(18/50)and 6.00%(3/50)of the middle and lower thoracic group(P<0.05).Conclusion The efficacy of radiotherapy in upper cervical thoracic esophageal cancer is more ideal than lower middle thoracic esophageal cancer,which can improve the long-term efficacy and survival rate of upper cervical thoracic esophageal cancer.